[ad_1]
Late Tuesday, Exelixis (EXEL) reported adjusted profit of 28 cents per share on $419.4 million in second-quarter sales. In response, EXEL stock remained flat.
X
On average, analysts polled by FactSet expected the cancer-focused biotech to report earnings of 19 cents per share and $391 million in sales.
In the year-earlier period, Exelixis earned 38 cents a share and reported $385.2 million in sales.
For the year, Exelixis maintained its outlook for $1.525 billion to $1.625 billion in total sales. EXEL stock analysts predicted adjusted income of 89 cents a share on $1.59 billion in sales.
In after-hours trading on today’s stock market, EXEL stock was flat near its closing price at 21.06. Exelixis shares are highly rated, according to IBD Digital. They have a Composite Rating of 96, which puts EXEL stock in the top 4% of all stocks in terms of fundamental and technical measures.
Its Relative Strength Rating of 91 puts Exelixis stock in the leading 9% of all stocks in terms of 12-month performance.
More to follow.
Follow Allison Gatlin on Twitter @IBD_AGatlin.
YOU MAY ALSO LIKE:
Why No. 1 Biotech Amphastar Crashed As Runaway Syndax Hit A Profit-Taking Zone
Novavax Stock Plummets As ‘Market Dynamics’ Crush Its 2022 Sales Outlook
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
Looking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists
Run Custom Stock Screens With MarketSmith
[ad_2]
Source link
